These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 27920507)

  • 1. Men's preferences for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia: a discrete choice experiment.
    Mankowski C; Ikenwilo D; Heidenreich S; Ryan M; Nazir J; Newman C; Watson V
    Patient Prefer Adherence; 2016; 10():2407-2417. PubMed ID: 27920507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Eliciting preferences for drug treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Watson V; Ryan M; Brown CT; Barnett G; Ellis BW; Emberton M
    J Urol; 2004 Dec; 172(6 Pt 1):2321-5. PubMed ID: 15538258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Best of Both Worlds: An Example Mixed Methods Approach to Understand Men's Preferences for the Treatment of Lower Urinary Tract Symptoms.
    Ikenwilo D; Heidenreich S; Ryan M; Mankowski C; Nazir J; Watson V
    Patient; 2018 Feb; 11(1):55-67. PubMed ID: 28660567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does one size fit all? Investigating heterogeneity in men's preferences for benign prostatic hyperplasia treatment using mixed logit analysis.
    Eberth B; Watson V; Ryan M; Hughes J; Barnett G
    Med Decis Making; 2009; 29(6):707-15. PubMed ID: 19734440
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Men's preferences and trade-offs for prostate cancer screening: a discrete choice experiment.
    Howard K; Salkeld GP; Patel MI; Mann GJ; Pignone MP
    Health Expect; 2015 Dec; 18(6):3123-35. PubMed ID: 25382490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies.
    Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C
    J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burden of benign prostatic hyperplasia among men in Japan: Patient-reported outcomes among those diagnosed and experiencing symptoms.
    Yoshida M; Flores NM; Vietri J; Lee M; Murakami M
    Int J Urol; 2015 Oct; 22(10):949-55. PubMed ID: 26138017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study.
    McVary KT; Gange SN; Gittelman MC; Goldberg KA; Patel K; Shore ND; Levin RM; Rousseau M; Beahrs JR; Kaminetsky J; Cowan BE; Cantrill CH; Mynderse LA; Ulchaker JC; Larson TR; Dixon CM; Roehrborn CG
    J Sex Med; 2016 Jun; 13(6):924-33. PubMed ID: 27129767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial.
    Kaplan SA; Roehrborn CG; Rovner ES; Carlsson M; Bavendam T; Guan Z
    JAMA; 2006 Nov; 296(19):2319-28. PubMed ID: 17105794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline Lower Urinary Tract Symptoms in Patients Enrolled in LURN: A Prospective, Observational Cohort Study.
    Cameron AP; Lewicky-Gaupp C; Smith AR; Helfand BT; Gore JL; Clemens JQ; Yang CC; Siddiqui NY; Lai HH; Griffith JW; Andreev VP; Liu G; Weinfurt K; Amundsen CL; Bradley CS; Kusek JW; Kirkali Z;
    J Urol; 2018 Apr; 199(4):1023-1031. PubMed ID: 29111381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.
    Mathias SD; Crosby RD; Nazir J; Klaver M; Drogendijk T; Hakimi Z; Odeyemi IA
    Value Health; 2014 Dec; 17(8):823-9. PubMed ID: 25498777
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia.
    Casabé A; Roehrborn CG; Da Pozzo LF; Zepeda S; Henderson RJ; Sorsaburu S; Henneges C; Wong DG; Viktrup L
    J Urol; 2014 Mar; 191(3):727-33. PubMed ID: 24096118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The evaluation of nocturia in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and the analysis of the curative effect after medical or placebo therapy for nocturia: a randomized placebo-controlled study.
    Xue Z; Lin Y; Jiang Y; Wei N; Bi J
    BMC Urol; 2018 Dec; 18(1):115. PubMed ID: 30545338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of phytotherapy on utility scores for 5 benign prostatic hyperplasia/lower urinary tract symptoms health states.
    Dedhia RC; Calhoun E; McVary KT
    J Urol; 2008 Jan; 179(1):220-5. PubMed ID: 18001791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study).
    Montorsi F; Gandaglia G; Chapple C; Cruz F; Desgrandchamps F; Llorente C
    Int J Urol; 2016 Jul; 23(7):572-9. PubMed ID: 26969887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing Aspects of Male Sexual Functions Accompanying Treatment of Benign Prostatic Hyperplasia With Silodosin 8 mg Per Day.
    ; Cihan A; Kazaz İO; Yıldırım Ö; Deliktaş H; Ongün Ş; Gül Ü; Şahin B; Üre İ; Özkara H
    J Sex Med; 2020 Jun; 17(6):1094-1100. PubMed ID: 32217036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
    Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
    J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.